Update on Department of Health and Human Services guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.
about
Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort studyUse of HAART among young people living with HIV.Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?A factor analytic study of the Italian National Institute of Health Quality of Life - Core Evaluation Form (ISSQoL-CEF).Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trialEffect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionCurrent practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care.Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance.cART prescription trends in a prospective HIV cohort in rural Tanzania from 2007 to 2011.Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014The HIV Care Continuum: Changes over Time in Retention in Care and Viral SuppressionRisk factors for missed HIV primary care visits among men who have sex with men.HAART-associated dyslipidemia varies by biogeographical ancestry in the multicenter AIDS cohort studyTest-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County.Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapySocial networks of substance users with HIV infection: application of the Norbeck Social Support Scale.Factors influencing lopinavir and atazanavir plasma concentration.Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort.Comparison of Matrix-Based and Filter Paper-Based Systems for Transport of Plasma for HIV-1 RNA Quantification and Amplicon Preparation for Genotyping.Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling.Perspectives on the role of patient-centered medical homes in HIV Care.
P2860
Q28081707-F317F75A-B9B5-414D-82EF-13A51293C3C7Q33644371-6D9F39EC-03EB-46F3-999E-25214D2B4149Q33720712-F1708CC7-E83E-4A67-86A8-D25A12EC9FE1Q33755732-8A0E3777-6007-42D7-9C42-9943506EC70BQ33926151-C87D8661-531F-4B7D-A337-467F8AD7FB9DQ34309475-2EAEBE29-D3B9-4EC9-A95C-10927A924DBEQ34408313-F2EF3F31-9FF6-4B02-884F-07AEAE51D423Q34546011-A5EC32E3-07D1-4507-909A-8BD19669875EQ34606742-3712FA44-8BF8-4515-9DC6-B37BD308EDEFQ34736194-23830E5F-126E-4D0F-809F-3303DFBEC84BQ34787977-326AE38C-027F-4A1A-A1A6-0A4887F93194Q34976284-1D337C38-C691-4F3A-A65F-AB2CAF4956F6Q35029328-0F421B6B-8D46-48CB-BCF7-5EBB474C84D3Q35051539-2EECBE90-A417-46AC-A970-D101F1580309Q35098097-96252459-7999-4B35-B382-53AF0F514232Q35628276-85FF52DD-3632-4766-84A5-0004D72BD96EQ35666922-23B24301-8733-426E-8A2C-A6D3247574DAQ36802328-2CC698F6-00A5-4859-9FA9-A096D1B33206Q36842181-C9B02446-EB22-486D-8777-CB802F890E60Q36856942-9FBED102-3E43-4F21-B43A-4EF8BA9D522AQ37042436-35293FD0-FEB0-4E5D-B139-FB351822432DQ37413346-B8C739BE-D73B-4FF3-BBEA-0F078254EF52Q37476403-0052E92D-E9AA-4EC0-A60B-A04B3EFA27FFQ37617342-68150F70-67A1-4BEA-94DC-F7E6246A2BA2Q40715383-49AC221F-9CD1-4F3C-8C2E-7F0941E0B733Q42919375-B7234ADA-4FB7-44F8-90C9-99B23F078561Q51834502-41430EF3-12AB-488A-8F8A-93A3B6AC0196
P2860
Update on Department of Health and Human Services guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Update on Department of Health ...... fected adults and adolescents.
@en
Update on Department of Health ...... fected adults and adolescents.
@nl
type
label
Update on Department of Health ...... fected adults and adolescents.
@en
Update on Department of Health ...... fected adults and adolescents.
@nl
prefLabel
Update on Department of Health ...... fected adults and adolescents.
@en
Update on Department of Health ...... fected adults and adolescents.
@nl
P1476
Update on Department of Health ...... nfected adults and adolescents
@en
P2093
J G Bartlett
P577
1999-07-01T00:00:00Z